|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-11-12
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
New-onset diabetes mellitus after transplantation (NODAT), a frequent and serious complication after transplantation, is associated with decreased graft and patient survival. Currently, it is diagnosed and treated primarily according to existing guidelines for type II diabetes. To date, only a few trials have studied antidiabetic drugs in patients with NODAT. Vildagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor that improves pancreatic islet function by enhancing both ?- and ?-cell responsiveness to increased blood glucose. Experimental data show potential protective effects of DPP-4 inhibitors on islet function after exogenous stress stimuli including immunosuppressants. Therefore, the therapy of NODAT with this class of compounds seems attractive. At present, vildagliptin is used to treat type II diabetes as monotherapy or in combination with other antidiabetic drugs, since that it efficiently decreases glycated hemoglobin (HbA1c) values. Additionally, vildagliptin has been shown to be safe in patients with moderately impaired kidney function. This study will evaluate the safety and efficacy of vildagliptin monotherapy in renal transplant recipients with recently diagnosed NODAT.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adamantane,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Dipeptidyl-Peptidase IV Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrrolidines,
http://linkedlifedata.com/resource/pubmed/chemical/hemoglobin A1c protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/vildagliptin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1745-6215
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
91
|
|
pubmed:meshHeading |
pubmed-meshheading:20925938-Adamantane,
pubmed-meshheading:20925938-Austria,
pubmed-meshheading:20925938-Biological Markers,
pubmed-meshheading:20925938-Blood Glucose,
pubmed-meshheading:20925938-Clinical Protocols,
pubmed-meshheading:20925938-Diabetes Mellitus,
pubmed-meshheading:20925938-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:20925938-Double-Blind Method,
pubmed-meshheading:20925938-Glucose Tolerance Test,
pubmed-meshheading:20925938-Hemoglobin A, Glycosylated,
pubmed-meshheading:20925938-Humans,
pubmed-meshheading:20925938-Hypoglycemia,
pubmed-meshheading:20925938-Hypoglycemic Agents,
pubmed-meshheading:20925938-Kidney Transplantation,
pubmed-meshheading:20925938-Nitriles,
pubmed-meshheading:20925938-Placebo Effect,
pubmed-meshheading:20925938-Prospective Studies,
pubmed-meshheading:20925938-Pyrrolidines,
pubmed-meshheading:20925938-Research Design,
pubmed-meshheading:20925938-Time Factors,
pubmed-meshheading:20925938-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.
|
|
pubmed:affiliation |
Clinical Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase II
|
